Market Place
Sourcing Support
ASLAN Pharmaceuticals Files For Voluntary Liquidation
17 Jul 2024 //
GLOBENEWSWIRE
Aslan’s dream of challenging Dupixent dies as cash-strapped biotech winds down
17 Jul 2024 //
FIERCE BIOTECH
ASLAN Pharmaceuticals Receives Nasdaq Delisting Determination
15 Jul 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
14 Jun 2024 //
GLOBENEWSWIRE
ASLAN Presents Eblasakimab COPD Translational Data At ATS
21 May 2024 //
GLOBENEWSWIRE
ASLAN Pharma Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
ASLAN On Eblasakimab Data In Atopic Dermatitis From TREK-DX Study
07 May 2024 //
GLOBENEWSWIRE
ASLAN, Zenyaku Expand Eblasakimab Collaboration
02 May 2024 //
GLOBENEWSWIRE
ASLAN KOL Panel on AD Treatment Options Post-Dupilumab
30 Apr 2024 //
GLOBENEWSWIRE
ASLAN`s Eblasakimab COPD Abstract at ATS Conference
24 Apr 2024 //
GLOBENEWSWIRE
ASLAN`s Eblasakimab Positive Interim Atopic Dermatitis Data
22 Apr 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
19 Apr 2024 //
GLOBENEWSWIRE
ASLAN Pharma Q4 & FY 2023 Results, Update
12 Apr 2024 //
GLOBENEWSWIRE
Aslan to Present at the 2nd Annual H.C. Virtual Conference
27 Mar 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
12 Mar 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Provides TREK-DX Study Update
11 Mar 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab
06 Mar 2024 //
GLOBENEWSWIRE
ASLAN Announces Receipt of Nasdaq Deficiency Notice
08 Jan 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
02 Jan 2024 //
GLOBENEWSWIRE
ASLAN Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
12 Dec 2023 //
GLOBENEWSWIRE
ASLAN to Participate in the 35th Annual Piper Sandler Healthcare Conference
20 Nov 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis
03 Nov 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results
27 Oct 2023 //
GLOBENEWSWIRE
ASLAN to Co-Host Panel Discussion on Changes in Trial for Atopic Dermatitis
18 Oct 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab
13 Oct 2023 //
GLOBENEWSWIRE
ASLAN Announces Acceptance of Late Breaker Abstract on Eblasakimab Ph 2b Results
22 Sep 2023 //
GLOBENEWSWIRE
ASLAN to Present at H.C. Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
ASLAN to Host Webcastto Discuss Phase 2b Data From TREK-AD Trial
05 Jul 2023 //
GLOBENEWSWIRE
ASLAN Announces Publication in Clinical Immunology Highlighting Eblasakimab
23 Jun 2023 //
GLOBENEWSWIRE
Aslan sells Japanese rights to would-be Dupixent rival for $12M
22 Jun 2023 //
FIERCE BIOTECH
Aslan outlicenses atopic dermatitis antibody in $138.5M deal
22 Jun 2023 //
ENDPTS
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
ASLAN doses first subject in alopecia areata therapy trial
19 May 2023 //
CLINICAL TRIALS ARENA
ASLAN Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
18 May 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat
15 May 2023 //
GLOBENEWSWIRE
ASLAN Announces Four Abstracts on Eblasakimab and Farudodstat
24 Apr 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
28 Mar 2023 //
GLOBENEWSWIRE
ASLAN Reports Fourth Quarter and Full Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
ASLAN to Participate in Fireside Chat at H.C. Wainwright Autoimmune Conference
22 Mar 2023 //
GLOBENEWSWIRE
ASLAN Announces Acceptance of Two Abstracts for Poster Presentation
14 Mar 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
10 Mar 2023 //
GLOBENEWSWIRE
ASLAN to Host R&D Day on Novel DHODH Inhibitor Farudodstat
08 Mar 2023 //
GLOBENEWSWIRE
ASLAN to Advance DHODH Inhibitor Farudodstat Into PII for Alopecia Areata
28 Feb 2023 //
GLOBENEWSWIRE
ASLAN Announces Completion of Recruitment in P2b TREK-AD Study of Eblasakimab
24 Feb 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P.
24 Feb 2023 //
GLOBENEWSWIRE
ASLAN Pharma and Thermo Fisher Scientific Announce Partnership
03 Jan 2023 //
GLOBENEWSWIRE
Aslan, Thermo Fisher Ink Clinical Manufacturing Deal
03 Jan 2023 //
CONTRACT PHARMA
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
16 Dec 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab
15 Dec 2022 //
GLOBENEWSWIRE
ASLAN to Participate in a Fireside Chat at Piper Sandler Healthcare Conference
21 Nov 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference
08 Nov 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking
28 Sep 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab
14 Sep 2022 //
GLOBENEWSWIRE
ASLAN Announces Acceptance of Two Late-Breaking Abstracts
13 Sep 2022 //
GLOBENEWSWIRE
ASLAN Presents New Data on Eblasakimab in Multiple Posters at the 31st (EADV)
07 Sep 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th
02 Sep 2022 //
GLOBENEWSWIRE
Aslan Pharma Signs License Agreement With Belle.AI To Use Bellestudy
25 Aug 2022 //
PRNEWSWIRE
ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022
22 Aug 2022 //
GLOBENEWSWIRE
ASLAN Pharma Reports Second Quarter 2022 Financial Results & Corporate Update
12 Aug 2022 //
GLOBENEWSWIRE
